EUVIMEDEUVIMED entdecken
Crossref

A Comparison of Injectable Diazepam and Lorazepam in the Goal-Directed Management of Severe Alcohol Withdrawal

Kendall H Brickel, Emily K Hodge, Daria Zavgorodnyaya, John M Schroeder, Lawrence H Brown, Mitchell J Daley iD

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231194790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Kendall H Brickel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Dell Seton Medical Center, The University of Texas, Austin, TX, USA. Hauptthemen laut MEDLINE: Substance Withdrawal Syndrome, Alcoholism. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Benzodiazepines are the gold standard for treatment of alcohol withdrawal, yet the selection of a preferred benzodiazepine is limited due to a lack of comparative studies.

Objectives

The primary objective of this study was to compare the efficacy and safety of injectable lorazepam (LZP) and diazepam (DZP) in the treatment of severe alcohol withdrawal syndrome (AWS).

Methods

Retrospective cohort study of adult patients admitted to an intensive care unit with a primary diagnosis of AWS. Subjects who received at least 12 LZP equivalent units (LEU) of injectable DZP or LZP within 24 hours of initiation of the severe AWS protocol were included. The primary outcome was time with Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA-Ar) scores at goal over the first 24 hours of treatment.

Results

A total of 191 patients were included (DZP n = 89, LZP n = 102). Time with CIWA-Ar scores at goal during the first 24 hours was similar between groups (DZP 12 hours [interquartile range, IQR, = 9-15] vs LZP 14 hours [IQR = 10-17]), P = 0.06). At 24 hours, LEU requirement was similar (DZP 40 [IQR = 22-78] vs LZP 32 [IQR = 18-56], P = 0.05). Drug cost at 24 hours was higher in the DZP group ($204.6 [IQR = 112.53-398.97] vs $8 [IQR = 4.5-14], P < 0.01). Conclusion and Relevance: DZP or LZP are equally efficacious for the treatment of severe AWS. LZP may be preferred due to cost but both medications can be used interchangeably based on availability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance Withdrawal SyndromeAlcoholismAdultHumansLorazepamDiazepamRetrospective StudiesGoalsBenzodiazepinesEthanol

Stichwörter der Autor:innen

alcoholismdiazepamlorazepamsubstance withdrawal syndrome

Substanzen

LorazepamDiazepamBenzodiazepinesEthanol

Autor:innen und Institutionen

  • Department of Pharmacy, Dell Seton Medical Center, The University of Texas, Austin, TX, USA.
  • Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas, Austin, TX, USA.

ORCID-Profile: Mitchell J Daley

Zitieren

APA

Brickel, K. H., Hodge, E. K., Zavgorodnyaya, D., Schroeder, J. M., Brown, L. H., & Daley, M. J. (2024). A Comparison of Injectable Diazepam and Lorazepam in the Goal-Directed Management of Severe Alcohol Withdrawal. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231194790

Vancouver

Brickel KH, Hodge EK, Zavgorodnyaya D, Schroeder JM, Brown LH, Daley MJ. A Comparison of Injectable Diazepam and Lorazepam in the Goal-Directed Management of Severe Alcohol Withdrawal. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231194790

BibTeX
@article{Brickel2024,
  author = {Brickel, Kendall H and Hodge, Emily K and Zavgorodnyaya, Daria and Schroeder, John M and Brown, Lawrence H and Daley, Mitchell J},
  title = {A Comparison of Injectable Diazepam and Lorazepam in the Goal-Directed Management of Severe Alcohol Withdrawal},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231194790}
}
Kostenlos starten →